BDH Industries Share Price & Earnings Call Analysis

Financials of BDH Industries

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of BDH Industries

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +22.7218.3119.3521.0627.1116.2616.2316.2017.8218.6218.9629.3429.03
Expenses +20.2016.3516.1817.5723.3014.3013.1812.6714.7516.5015.6325.1124.82
Operating Profit2.521.963.173.493.811.963.053.533.072.123.334.234.21
OPM %11.09%10.70%16.38%16.57%14.05%12.05%18.79%21.79%17.23%11.39%17.56%14.42%14.50%
Other Income +0.340.370.410.370.430.380.430.460.570.550.550.530.61
Interest0.070.040.030.020.100.020.040.010.010.010.030.010.01
Depreciation0.130.130.130.130.180.220.230.230.230.220.220.220.22
Profit before tax2.662.163.423.713.962.103.213.753.402.443.634.534.59
Tax %28.20%25.00%26.61%25.07%25.25%25.24%25.23%25.07%26.76%25.00%27.82%22.96%37.25%
Net Profit +1.911.622.512.782.961.572.412.812.491.832.623.492.88
EPS in Rs3.322.814.364.835.142.734.194.884.323.184.556.065.00

Financials of BDH Industries

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +444643415259576974866796
Expenses +404238364551496064735582
Operating Profit4455799911121214
OPM %9%9%11%13%14%15%15%13%15%14%17%14%
Other Income +121111111222
Interest000011000000
Depreciation111111111111
Profit before tax45557891011131215
Tax %32%33%33%27%26%27%27%24%26%25%26%29%
Net Profit +33345667810911
EPS in Rs4.465.615.806.538.3910.3211.0512.5414.2417.1416.1018.78
Dividend Payout %39%37%36%36%34%25%28%29%28%26%28%27%

Financials of BDH Industries

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital666666666666
Reserves182123252832374349566371
Borrowings +9988139925912
Other Liabilities +191517181818191820231720
Total Liabilities525254576665716980938799
Fixed Assets +131323232221202019202019
CWIP040000000000
Investments000000000000
Other Assets +383531344444514961736780
Total Assets525254576665716980938799

Financials of BDH Industries

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +647-0-411136-215-2
Cash from Investing Activity +-0-5-5011110-022
Cash from Financing Activity +-3-1-3-33-6-2-801-10-2
Net Cash Flow3-1-1-206-0-47-16-2
Free Cash Flow6-01-1-411146-415-2
CFO/OP198%146%186%21%-24%153%35%64%82%11%153%8%

Financials of BDH Industries

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days81646763896896768212178120
Inventory Days716139958951535053306528
Days Payable20116219224418815817112313912813491
Cash Conversion Cycle-49-37-85-85-10-39-214-523958
Working Capital Days-76-72-90-60-29-316564971102116
ROCE %13%15%14%14%16%19%18%18%20%21%18%20%

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd